Stoked Bio is a translational biotechnology company established to develop new candidates for resistant infectious diseases and cancers identified using a unique, biology-driven ai-assisted drug discovery and optimization platform created and implemented in the Stokes Lab at McMaster University. Stoked Bio’s pipeline will consist of structurally and functionally novel, clinically relevant, easily synthesizable small molecules with validated therapeutic and toxicity profiles that overcome current resistance. Stoked will be responsible for the development of these validated candidates through the preclinical process with the goal of bringing several new therapeutics to IND, ready for first in human trials.
Leveraging leading-edge AI to create novel therapeutics against infections and cancer.
Interactively refining novel, therapeutically relevant scaffolds using world-leading AI to design the best drug candidate to treat underserved diseases.
Advancing the best development candidates against resistant bacterial, fungal, and cancer indications.
Stoked Bio is in the business of developing poisons.
Our goal is to develop poisons to efficiently kill what nature uses to kill us.
Through evolution, nature has learned how to evade some of our best weapons to keep us alive. Resistant infections and cancers are able to thrive even when our best treatments are used against them.
We need to develop new therapeutic options, with new mechanisms of action, if we want to keep treating these diseases and maintain human health on a global scale.
Using world-leading AI methods for therapeutic discovery and design, Stoked Bio has the unique ability to discover new treatments against important and life-threatening diseases. We are a self-sustaining, world-class Canadian drug research and development organization building collaborations with early-stage biotech businesses and concentrating on revenue-generating partnerships. Our mission is to create new therapeutic options against life-threatening disease, driving innovation and meeting urgent medical needs via a portfolio of ground-breaking therapies.
But we are biologists first. This means that our work isn’t done when the models are trained and applied. We are able to modify and iterate the best molecules to develop compounds with real potential to become new treatments for patients. Our work is about proving that these candidates can become drugs through rigorous preclinical refinement. And because we have an almost endless stream of new molecules coming from our early discovery efforts, we will drop any compound that doesn’t show a clear path to clinical development.
Stoked Bio is dedicated to promoting drug development, guaranteeing fair access to life-saving therapies, and having a significant influence on global public health.
We are not an AI company. We are a drug discovery and development company that uses world-leading AI methods as a starting point to accelerate solutions to real problems and fill the pipeline for new drugs with new ways to treat drug-resistant diseases.
